Reports First-half 2018 Financial Results and Provides a Corporate Update
Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor
Of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease
To Present at the 2018 JMP Securities Life Sciences Conference
To Present at the Jefferies 2018 Global Healthcare Conference
Dr Lucy Lu is appointed to the Inventiva Board of Directors
Lanifibranor: Phase IIb trial in NASH, recruiting now
Lanifibranor: Phase IIb trial in Systemic Sclerosis.
Odiparcil: Phase IIa in MPSVI, recruiting now
No front page content has been created yet.